PDF(Pubmed)
Abstract：
OBJECTIVE: Stereotactic body radiotherapy is increasingly used for the treatment of oligometastatic disease. Magnetic resonance-guided stereotactic radiotherapy (MRgSBRT) offers the opportunity to perform dose escalation protocols while reducing the unnecessary irradiation of the surrounding organs at risk. The aim of this retrospective, monoinstitutional study is to evaluate the feasibility and clinical benefit (CB) of MRgSBRT in the setting of oligometastatic patients.
METHODS: Data from oligometastatic patients treated with MRgSBRT were collected. The primary objectives were to define the 12-month progression-free survival (PFS) and local progression-free survival (LPFS) and 24-month overall survival (OS) rate. The objective response rate (ORR) included complete response (CR) and partial response (PR). CB was defined as the achievement of ORR and stable disease (SD). Toxicities were also assessed according to the CTCAE version 5.0 scale.
RESULTS: From February 2017 to March 2021, 59 consecutive patients with a total of 80 lesions were treated by MRgSBRT on a 0.35 T hybrid unit. CR and PR as well as SD were observed in 30 (37.5%), 7 (8.75%), and 17 (21.25%) lesions, respectively. Furthermore, CB was evaluated at a rate of 67.5% with an ORR of 46.25%. Median follow-up time was 14 months (range: 3-46 months). The 12-month LPFS and PFS rates were 70% and 23%, while 24-month OS rate was 93%. No acute toxicity was reported, whereas late pulmonary fibrosis G1 was observed in 9 patients (15.25%).
CONCLUSIONS: MRgSBRT was well tolerated by patients with reported low toxicity levels and a satisfying CB.
METHODS: Data from oligometastatic patients treated with MRgSBRT were collected. The primary objectives were to define the 12-month progression-free survival (PFS) and local progression-free survival (LPFS) and 24-month overall survival (OS) rate. The objective response rate (ORR) included complete response (CR) and partial response (PR). CB was defined as the achievement of ORR and stable disease (SD). Toxicities were also assessed according to the CTCAE version 5.0 scale.
RESULTS: From February 2017 to March 2021, 59 consecutive patients with a total of 80 lesions were treated by MRgSBRT on a 0.35 T hybrid unit. CR and PR as well as SD were observed in 30 (37.5%), 7 (8.75%), and 17 (21.25%) lesions, respectively. Furthermore, CB was evaluated at a rate of 67.5% with an ORR of 46.25%. Median follow-up time was 14 months (range: 3-46 months). The 12-month LPFS and PFS rates were 70% and 23%, while 24-month OS rate was 93%. No acute toxicity was reported, whereas late pulmonary fibrosis G1 was observed in 9 patients (15.25%).
CONCLUSIONS: MRgSBRT was well tolerated by patients with reported low toxicity levels and a satisfying CB.
摘要：
目的：立体定向放射治疗越来越多地用于治疗寡转移疾病。磁共振引导的立体定向放射治疗（MRgSBRT）提供了执行剂量递增方案的机会，同时减少了对周围危险器官的不必要照射。这次回顾的目的，单机构研究旨在评估MRgSBRT在寡转移患者中的可行性和临床益处（CB）。
方法：收集接受MRgSBRT治疗的寡转移患者的数据。主要目标是确定12个月无进展生存期（PFS）和局部无进展生存期（LPFS）以及24个月总生存率（OS）。客观反应率(ORR)包括完全反应(CR)和部分反应(PR)。CB被定义为实现ORR和稳定的疾病(SD)。还根据CTCAE版本5.0量表评估毒性。
结果：从2017年2月至2021年3月，在0.35T混合单元上通过MRgSBRT治疗了59例连续患者，共80个病灶。在30例(37.5%)中观察到CR和PR以及SD，7（8.75%），和17个（21.25%）病变，分别。此外，CB的评价率为67.5%,ORR为46.25%。中位随访时间为14个月(3~46个月)。12个月的LPFS和PFS率分别为70%和23%，而24个月OS率为93%。无急性毒性报告，而在9例患者中观察到晚期肺纤维化G1（15.25％）。
结论：MRgSBRT在报告的低毒性水平和令人满意的CB患者中具有良好的耐受性。
方法：收集接受MRgSBRT治疗的寡转移患者的数据。主要目标是确定12个月无进展生存期（PFS）和局部无进展生存期（LPFS）以及24个月总生存率（OS）。客观反应率(ORR)包括完全反应(CR)和部分反应(PR)。CB被定义为实现ORR和稳定的疾病(SD)。还根据CTCAE版本5.0量表评估毒性。
结果：从2017年2月至2021年3月，在0.35T混合单元上通过MRgSBRT治疗了59例连续患者，共80个病灶。在30例(37.5%)中观察到CR和PR以及SD，7（8.75%），和17个（21.25%）病变，分别。此外，CB的评价率为67.5%,ORR为46.25%。中位随访时间为14个月(3~46个月)。12个月的LPFS和PFS率分别为70%和23%，而24个月OS率为93%。无急性毒性报告，而在9例患者中观察到晚期肺纤维化G1（15.25％）。
结论：MRgSBRT在报告的低毒性水平和令人满意的CB患者中具有良好的耐受性。
